文献速递瓣膜外科

Tendyne经导管二尖瓣置换术中期临床结局:100例前瞻性队列随访至4年

Mid-Term Clinical Outcomes of Tendyne Transcatheter Mitral Valve Replacement: A Prospective Cohort of 100 Patients with Follow-up to 4 Years.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-10-09

本研究前瞻性纳入单中心连续100例高外科风险Tendyne经导管二尖瓣置换术患者,平均年龄76.3岁,STS预测死亡风险7.7%。技术成功96.0%,30天器械成功74.0%,Kaplan-Meier生存率30天90.0%、1年71.2%、2年64.3%、3年54.8%。2年时100%患者二尖瓣反流≤1+,84.9%心功能NYHA I/II级。

要点

  • Tendyne TMVR在高外科风险患者中技术成功率高,中期生存率逐年下降。
  • 2年随访显示持久二尖瓣反流消除和心衰症状缓解。
  • 按时间分组分析未发现显著学习曲线效应。

核心结论

  • Tendyne TMVR在异质性二尖瓣疾病队列中有效消除二尖瓣反流,无显著学习曲线证据,瓣膜功能持久至3年。
  • 中期死亡率与心血管和非心血管死亡相关。

研究设计与样本

  • 前瞻性单中心队列研究,连续纳入100例高外科风险接受Tendyne TMVR患者,随访至4年。
  • 按时间顺序分为4组(每组25例)分析30天死亡率以评估学习曲线。

主要发现

  • 平均年龄76.3±7.0岁,平均STS预测死亡风险7.7±6.4%。
  • 二尖瓣病变包括原发性MR 62.0%、功能性MR 29.0%、严重MAC 30%、既往二尖瓣干预19%。
  • 技术成功96.0%,30天器械成功74.0%。
  • Kaplan-Meier生存率:30天90.0%(95%CI 82.2-94.5%),1年71.2%(95%CI 61.1-79.2%),2年64.3%(95%CI 53.4-73.4%),3年54.8%(95%CI 41.7-66.1%)。
  • 2年超声显示100% MR≤1+(无/微量MR 84.4%),84.9% NYHA I/II级。

临床怎么用

  • 对于高外科风险且不适合TEER的合适二尖瓣解剖患者,Tendyne TMVR可有效消除MR并改善心衰症状。
  • 中期生存率有限,需权衡获益与死亡风险。

局限性

  • 单中心研究,样本量100例。
  • 随访至4年但部分结局数据截至3年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcatheter mitral valve replacement (TMVR) is an emerging therapy option currently mainly used in patients at high surgical risk and a mitral valve anatomy not eligible for transcatheter edge to edge repair (TEER). Clinical TMVR data are sparse as currently only two devices were granted CE or FDA certification. This study evaluates mid-term clinical outcomes of 100 consecutive single-center Tendyne-TMVR patients. METHODS: From the institutional TMVR database, the first 100 consecutive patients undergoing implantation of the Abbott Tendyne mitral valve were identified. Baseline and procedural characteristics, clinical and echocardiography follow-up were prospectively recorded and retrospectively analyzed and reported following MVARC recommendations. according To evaluate a procedure-specific learning curve, the cohort was analyzed for 30-day mortality across four consecutive chronological groups (n=25 each). RESULTS: The study enrolled 100 high surgical risk patients (mean age 76.3 ± 7.0 years; mean STS predicted risk of mortality 7.7 ± 6.4%). Mitral valve pathologies included primary MR (62.0%), functional MR (29.0%), severe MAC (30%) and previous mitral valve intervention (19%). Technical success was 96.0% and 30-day device success was 74.0%. Kaplan-Meier estimated survival at 30-days was 90.0% (95% CI: 82.2-94.5%), 71.2% (95% CI:61.1-79.2%) at 1 year, 64.3% (95% CI: 53.4-73.4%) at 2 years and 54.8% (95% CI: 41.7-66.1%) at 3 years. Chronological analysis revealed no significant inter-group differences in 30-day survival across the four groups composed of consecutive 25 patients (p=0.522).At 2 years, echocardiography revealed durable MR reduction with 100% MR Grade ≤1+ (none/trace MR 84.4%) and significant relief of heart failure symptoms with 84.9% NYHA class I/II. CONCLUSIONS: TMVR with the Tendyne mitral valve system provided effective MR elimination in a cohort presenting with heterogenous mitral valve disease without evidence for a significant learning curve. Durable mitral valve function was confirmed up to 3 years. Mid-term mortality is associated with cardiovascular and non-cardiovascular mortality.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Puluca N, Bonk MN, Voss S, et al. Mid-Term Clinical Outcomes of Tendyne Transcatheter Mitral Valve Replacement: A Prospective Cohort of 100 Patients with Follow-up to 4 Years. J Thorac Cardiovasc Surg. 2026. PMID: 42854830. doi:10.1016/j.jtcvs.2026.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。